News

HDA UK MEDIA AND POLITICAL BULLETIN – 15 August 2017

MEDIA SUMMARY 

Three quarters of drugs in Cancer Drugs Fund now approved for routine use
The Pharmaceutical Journal, 14 August 2017

The Pharmaceutical Journal, and the European Pharmaceutical Review (Dr Zarra Kassam, 14 August 2017) have reported on the recent NICE approval of three quarters of the drugs currently in the Cancer Drugs Fund. This means that over 75% of the drugs included in the CDF are now available for routine use on the NHS. The National Institute for Health Care and Excellence (NICE) ok’ed the drugs.The CDF was originally implemented in 2010 to ensure that patients were able to access drugs not available for regular use. However, the scheme quickly overran its £200 million budget, and thus NICE was asked to review all the drugs under the program and assign some for routine use. So far at least 24 drugs have been approved for regular prescription.

PARLIAMENTARY COVERAGE

There is no parliamentary coverage.

FULL COVERAGE 

Three quarters of drugs in Cancer Drugs Fund now approved for routine use
The Pharmaceutical Journal, 14 August 2017

The National Institute for Health and Care Excellence (NICE), the health technology assessment body, has now approved three quarters of the drugs in the Cancer Drugs Fund (CDF) for routine NHS use, and has not rejected any drug outright.

Liver cancer drug sorafenib (Nexavar; Bayer) is the 18th of the 24 drugs in the CDF that NICE was asked to appraise and has recommended should be routinely available for some patients on the NHS.

The CDF was established by the government in 2010 as a temporary solution to help patients access cancer drugs that were not widely available on the NHS. However, the fund quickly exceeded its budget, and in 2016 reforms were put in place which required NICE to carry out appraisals for the drugs in the existing fund and all newly licensed cancer drugs.

Professor Carole Longson, director of the NICE centre for health technology evaluation said: “More cancer drugs than ever are being recommended for routine use because companies are working hard to provide cost-effective solutions. We are also applying flexibility in cases where drugs show promise, meaning people get access through the new CDF while further data is generated.”

Sorafenib has been recommended for some people with liver cancer that has progressed. It is estimated that the drug extends life by up to three months.

NICE approves three quarters of the Cancer Drugs Fund
The European Pharmaceutical Review, Dr Zarra Kassam, 14 August 2017

The Nation Institute for Health Care and Excellence (NICE)  has recommended sorafenib, to be routinely available for some patients on the National Health Service (NHS), sorafenib is one of the 24 drugs NICE was asked to appraise from the Cancer Drug Fund (CDF), all of which have been approved so far for routine use.

The CDF is a source of funding for cancer drugs in England, that provides patients with faster access to the most promising new cancer treatments as well as helps to ensure more value for money for taxpayers. Additionally CDF offers pharmaceutical companies a new fast-track route to NHS funding.

“More cancer drugs than ever are being recommended for routine use because companies are working hard to provide cost-effective solutions. We are also applying flexibility in cases where drugs show promise, meaning people get access through the new CDF while further data is generated.”

The CDF was established by the Government in 2010 as a temporary solution to help patients to access cancer drugs that were not widely available on the NHS. However, the fund quickly exceeded its original £200m budget. In 2016 reforms were put in place which required NICE to carry out appraisals for the drugs in the existing fund and all newly licensed cancer drugs.

Sorafenib is recommended for some people with liver cancer that has progressed. It is estimated that the drug extends life by up to 3 months. The guidance is now with consultees who have the opportunity to appeal against it.

Companies, such as Bayer have provided discounts and in some cases additional evidence meaning the drugs can be considered as cost effective for routine NHS. Professor Carole Longson, director of the NICE centre for health technology evaluation said: “Working closely with companies and NHS England, we are delivering our promise to give people fast access to the most cost-effective cancer drugs.”

HDA UK MEDIA AND POLITICAL BULLETIN – 15 August 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?